581 Midterm Flashcards
Gram + bacteria characteristics
thick peptidoglycan layer that stains purple violet; allows bacteria to survive unfavorable conditions in “suspended animation.” Allows you to determine how to treat certain diseases and/or what kind of treatment
Clostridium difficile
gram + spore forming bacillus that causes GI disease. It lives naturally in gut flora. Due to factors that disturb the gut flora environment, this opportunistic organism grows at rates causing diarrhea & abdominal pain.
Risk factors for c.diff
abx use: fluoroquinolone (cipro, levofloxacin) and clindamycin age gastric aid suppression GI surgery Long length of stay in hospital serious underlying illness
C.diff microbiology
Gram + anaerobic spore forming bacteria that produces:
- Enterotoxin A
- Cytotoxin B
C.diff Toxin A
Enterotoxin that destroys tight cell junctions = INC permeability of the intestinal wall = diarrhea; nonvirulent
C.diff Toxin B
Cytotoxin that targets actin and destroys cellular cytoskeletons; essential for virulence
What does c.diff do to the gut?
- colonocyte death
- loss of intestinal barrier function
- neutrophillic colitis
- inflammation and fluid buildup
- inflamed cells burst & die
- spores leave colon via diarrhea
C.diff disease presentation
Watery diarrhea Low abdominal pain, cramping low grade fever nausea elevated WBC
Diseases caused by c.diff
psudomembranous colitis PMC toxic megacolon perforations of the colon sepsis death
C.diff diagnosis
toxin detection in feces; no way to distinguish active infection v carrier state
Use this test for patients in-hospital who are having symptoms
C.diff Treatment
stop taking abx
place in isolation precautions
oral vancomycin or fidaxomicin; if one fails try the other
fecal transplant if recurrent
C.diff prevention and control
contact precautions: single patient room, use of gloves/gown by those that come in
wash hands
Clean rooms with sporicidal antiseptics
Use disposable equipment
5 steps to drug research
- discovery & development
- preclinical research
- clinical research
- FDA review
- post market monitoring
4 clinical trial phases
- assess drug safety/dosage; 20-100 healthy volunteers with the disease/condition; 70% move forward
- efficacy and side effects; 100s of people; 33%
- compare new and current treatment; 100s-1000s of volunteers; 25-30%
- safety and efficacy: several thousand volunteers
Genetically engineered monoclonal antibodies
specifically bind to a substance
Bezlotoxumab binds to c.diff toxin B
Actoxumab binds to c.diff toxin A